View More
In my practice, I choose the most effective treatment across the board to control blood sugar and reduce the risk for complications from renal, cardiovascular, and other common comorbidities.
Zachary T. Bloomgarden, MD, MACE
Physicians:
maximum of 0.4 AMA PRA Category 1 Credits™
Registered Nurses:
0.4 Nursing contact hours
Released: March 2, 2020
Expired: March 1, 2021
For patients with T2D and cardiovascular disease, we are fortunate to have several GLP-1 receptor agonists with an indication for reducing the risk of major adverse cardiovascular events. Here’s my approach to choosing among them.
Anne Peters, MD
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.25 Nursing contact hours
Released: June 8, 2020
Expired: June 7, 2021
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.